Selpercatinib – March 2026

Capsule 40 mg, Capsule 80 mg

  • Brand names:
    • Retevmo®
  • Pharmaceutical Company:
    • ELI LILLY AUSTRALIA PTY LTD
  • Condition/Indication: Medullary thyroid cancer (MTC)
  • Meeting Date: March 2026
Public Summary Documents
Last updated
11 March 2026